A f fec tive dis or ders are char ac ter ized, first, by a high risk of re cur rence and, sec ond, by mor tal ity rates that are 2 to 3 times higher than rates in the gen eral pop u la tion (1-4). Excess mor tal ity among those with af fec tive dis or ders is attrib ut able pri mar ily to sui cide-induced mor tal ity, for which rates are pos si bly 30 to 70 times higher (5)-and 100% higher in pa tients with a his tory of sui cide at tempts (6,7)-but it is also at trib ut able to car dio vas cu lar ex cess mor tal ity. According to Goodwin and Jamison, who an a lyzed 21 ex isting stud ies (n = 6000 pa tients) to in ves ti gate the as so ci a tion of sui cide and af fec tive dis or ders, 30% of pa tients with af fec tive dis or ders died from sui cide (8). Fur ther, a long-term study from Ice land re ports that 52% of pa tients ex am ined ended their lives (9). Guze and Robins' of ten-quoted metaanalysis cal cu lated a life time sui cide risk of 15% for in di vid u als with af fec tive dis or ders (10), whereas Goodwin and Jamison reported an over all risk of 19%, based on more re cent lit er a ture (11). When sam ples of pa tients with milder forms of af fec tive dis or ders were an a lyzed-for ex am ple, those who were never hos pi tal ized-the life time sui cide rates ap peared to be much lower (12,13).
The sui cide-related mor tal ity among pa tients with af fec tive dis or ders is ap prox i mately 30 times higher, and over all mor tal ity 2 to 3 times higher, than sui cide-related mor tal ity in the gen eral pop u la tion. Lith ium has dem on strated pos si bly spe cific antisuicidal ef fects apart from its pro phy lac tic ef fi cacy: it sig nif i cantly re duces the high ex cess mor tal ity of pa tients with af fec tive dis or ders. To date, sui cide-prevention ef fects have not been shown for an tide pres sant or anticonvulsant long-term treat ment. Clozapine ap pears to re duce the sui cide rate in schizo phre nia pa tients. Against this back ground, guide lines and al go rithms for select ing an ap pro pri ate pro phy lac tic strat egy for af fec tive dis or ders should con sider the pres ence of suicidality in pa tient his tory. Ap pro pri ate lith ium pro phy laxis pre vents ap proxi mately 250 sui cides yearly in Ger many, al though lith ium salts are in fre quently pre scribed within the Na tional Health Scheme (spe cif i cally, to 0.06% of the pop u la tion). Ra tio nal treat ment strat e gies most likely would de mand that pre scrip tion rates be about 10 times higher. In for ma tion on au thor af fil i a tions ap pears at the end of the ar ti cle.
High lights
· Ex cess mor tal ity is marked among in di vid u als with af fec tive dis or ders. There fore, re duced sui cide risk and mor tal ity must be an es sen tial end point in eval u at ing the ef fec tive ness of long-term an ti de pres sive or mood-stabilizing strat e gies. · Lith ium salts are the only com pounds for which many stud ies have shown such ef fects with suf fi cient ev i dence.
com pared with uni po lar dis or der patients (for exam ple, 16, 17) , oth ers found higher rates in BD patients (18) (19) (20) .
Against this back ground, there fore, effec tive pro phy laxis is of utmost impor tance for patients with affec tive dis or ders, and sui cide pre ven tion must be regarded as a deci sive end point for assess ing the out come of long-term treat ment of affec tive dis or ders.
As we out line below, strong evi dence has accu mu lated dur ing the last decade that lith ium pro phy laxis can pre vent sui cidal acts and reduce the excess mor tal ity of patients with affec tive disor ders. It is there fore pro vok ing and irri tat ing to observe that a great many-per haps most-patients with uni po lar dis or der or BD are not maintained on a proper, state-of-the-art prophy lac tic drug reg i men (21) . It has been esti mated that up to 50% of these patients, includ ing those who suf fer mul ti ple relapses and may there fore bear an increased sui cide risk, do not receive pro phy lac tic treat ment (22) . The Amer i can Psy chi at ric Asso ci a tion guide lines for the treat ment of depres sive dis or der do not even men tion lith ium as a pro phy lac tic agent (23) .
Assuming a pop u la tion prev a lence of 1% for BDs, at least 820 000 patients in Ger many need pro phy lac tic treat ment. Lith ium salts could prob a bly be con sid ered as first-line treatment for about one-half of them. Yet, accord ing to a rea sonable esti mate for the year 2001, about 50 000 patients in Ger many received lith ium med i ca tion within the National Health Scheme (24). The ques tion, then, is whether this discrep ancy does not reflect some sort of mal prac tice.
The Effect of Long-Term Lith ium Med i ca tion on Mor tal ity and Sui cide Rates of Patients With Affec tive Dis or ders
Whether unin ter rupted med i ca tion with lith ium salts can prevent sui cide and lower mor tal ity, thereby improv ing the course of manic depres sive dis or der, of recur rent depres sion, or even of schizoaffective dis or ders, is an intrigu ing ques tion that was given lit tle atten tion until the 1980s.
Barraclough was per haps one of the first inves ti ga tors to postu late an asso ci a tion between long-term lith ium med i ca tion and sui cide pre ven tion (25) . He ana lyzed the charts of 100 suicide vic tims: 64 vic tims had suf fered a major depres sion. Of these, 44 had epi sodic depres sion. Barraclough con cluded that about 20% of the sui cides could have been pre vented by ade quate lith ium med i ca tion. Kline reported on 3 cases in which lith ium med i ca tion as cri sis inter ven tion impres sively changed sui cidal thoughts or sui cidal behav iour (26) .
Müller-Oerlinghausen and oth ers pub lished the first sys tematic ret ro spec tive anal y sis to dem on strate a highly sig nif i cant reduc tion in sui cide attempts in a sam ple of high-risk patients receiv ing long-term lith ium treat ment (27) . The authors empha sized that sui cides and sui cide attempts occurred almost exclu sively in a group of 13 patients who had taken lith ium irreg u larly or had stopped the med i ca tion.
Felber and Kyber ana lyzed sui cide attempts dur ing accu mulated peri ods on and off lith ium: 90% of sui cide attempts occurred in the off-lithium period (28).
Coppen and oth ers (29) and the Inter na tional Group for the Study of Lith ium-Treated Patients (IGSLI; 30,31) stud ied mor tal ity among patients with affec tive dis or ders dur ing long-term lith ium treat ment. These stud ies dem on strated that, dur ing ade quate lith ium med i ca tion, the stan dard ized mor tality in this patient pop u la tion is nor mal ized down to the level in the gen eral pop u la tion. Coppen reviewed stud ies exist ing in the mid-1990s on sui cide rates in patients both on and off long-term lith ium treat ment (32) ( Table 1) . Accord ing to Coppen, ade quate lith ium med i ca tion reduces the suicide-related mor tal ity by 82%.
Studies inves ti gat ing poten tial effects of a ther a peu tic interven tion on sui cide rates dis play a com mon meth od olog i cal prob lem: esti mat ing how many deaths are to be expected in a matched, nontreated patient sam ple. Since it is not eth i cally pos si ble to treat a con trol group of patients suf fer ing from affec tive dis or ders with long-term pla cebo, the IGSLI used a ref er ence group from the gen eral pop u la tion in its stud ies. This makes it pos si ble to cal cu late the stan dard ized mor tal ity rate either for any causes of death or for spe cific causes such as car dio vas cu lar dis ease, acci dent, and sui cide.
The IGSLI Studies
The IGSLI stud ies began after the lith ium research group in Berlin observed that sui cidal behav iour was clearly decreased or even abol ished in lith ium-treated patients, includ ing those not show ing a sat is fac tory epi sode-preventive effect (27) . The IGSLI main study eval u ated detailed and well-documented data on the ill ness course of 827 patients from lith ium clin ics in Aus tria, Can ada, Den mark, and Ger many who had been treated with lith ium for at least 6 months (30, 15) . These patients had the fol low ing diag no ses: 55% BD, 25% uni po lar dis or der, 2% uni po lar-manic depres sion, 16% schizoaffective dis or der, and 2% "other." At the onset of lith ium pro phy laxis, patients were aged 41 years, on aver age. The mean dura tion of lith ium treat ment was 81 months (range, 6 to 21 years), equalling 5600 patient years.
As can be seen from Table 2 , the ratio of 44 observed to 38 expected deaths is not sta tis ti cally dif fer ent from 1.0, which is the mor tal ity rate in the gen eral pop u la tion. Thus, the expected 2 to 3 times higher excess mor tal ity in patients with affec tive dis or ders (see above) does not exist in this lithium-treated patient sam ple.
Although the sui cide-related SMR is still higher than the general pop u la tion rate (Table 2; 15) it can be clearly shown that it is def i nitely lower in all diag nos tic groups, com pared with that expected in untreated patient sam ples. Inter est ingly, the car dio vas cu lar SMR also appeared to be nor mal ized in the lith ium-treated patients.
It could be argued that patients who accept a lith ium pro phylaxis gen er ally ben e fit from a better prog no sis. If so, the specific patient selec tion would be pri mar ily respon si ble for the nor mal iza tion of the SMR. (Con versely, it could be assumed that patients for whom lith ium pro phy laxis is indi cated suf fer from a higher sui cide risk, owing to the higher mor bid ity.)
To study this issue, Müller-Oerlinghausen and oth ers fur ther ana lyzed 270 Ger man and Dan ish patients from the orig i nal IGSLI sam ple, com par ing the ini tial SMR with the SMR after treat ment of more than 1 year (33) . Dur ing the first year, overall mor tal ity was 2 times higher, and sui cide-related mor tal ity 17 times higher, com pared with the gen eral pop u la tion. However, the SMR nor mal ized after the first year of treatment, sug gest ing that patients for whom lith ium pro phy laxis is indi cated are in fact patients with a high risk of sui cide.
Studies Sup porting the IGSLI Find ings: the Effect of Dis con tinu a tion
Coppen and oth ers pre sented one of the first sys tem atic studies show ing reduced mor tal ity, mainly in patients with unipolar dis or ders treated with lith ium over par tic u larly long peri ods (29) . Norton and Whalley were not able to dem onstrate reduced mor tal ity in cohorts of lith ium-treated patients (34), nor were Vestergaard and Aagaard (35) . In both stud ies, how ever, lith ium treat ment dura tion was on aver age shorter than in the IGSLI study, and treat ment com pli ance may not have been suf fi ciently con trolled. For exam ple, in Vestergaard and Aagaard's study, one-third of the deaths took place after patients had dis con tin ued lith ium (35). Nilsson's study is note wor thy: inves ti gat ing in a dif fer ent set ting (specif i cally, an open field with no spe cial ized lith ium clin ics, as in most IGSLI cen tres), this author did not observe a full normal iza tion of the SMR (36). How ever, as observed in stud ies reviewed by Schou (37) , the SMR rose to the expected level after patients with untreated affec tive dis or ders dis con tin ued lith ium (Table 3) . Studies in a Sar din ian patient sam ple (38) and a recent Swed ish study (39) fur ther sup port the evi dence for lith ium's antisuicidal effect. The Swed ish study is par tic ularly inter est ing because it sug gests that the sui cidepreventing effect may be more marked among patients in specialized lith ium clin ics than in patients treated with rou tine med i cal care. A metaanalysis of about 17 000 patients with BD dem on strated that patients treated with out lith ium had an 8.6 times higher mor tal ity from sui cide, com pared with patients receiv ing long-term lith ium treat ment (40) .
Meth od olog i cal Prob lems in Cal cu lating Mor tal ity Rates
Although most exist ing stud ies sug gest that lith ium pro phylaxis reduces sui cide and mor tal ity, a few appar ently con tradic tory find ings also exist (see above). One rea son for this dis crep ancy may be dif fer ences in the ther a peu tic set ting and in treat ment dura tion. Another rea son may be dif fer ent ways of com put ing mor tal ity rates. To study this issue, Wolf and oth ers enlarged the data base of the IGSLI study by add ing mor tal ity data from 2 asso ci ated cen tres and reanalyzed the data, using 3 dif fer ent math e mat i cal approaches (41) . We stud ied the out come of 3 dif fer ent approaches:
1. the "cumu la tive approach," used by most authors, in which the accu mu la tion of the indi vid ual treat ment dura tion is used and SMR cal cu lated as the total num ber of observed deaths divided by the total num ber of expected deaths;
2. the "cumu la tive year-by-year approach," in which SMR is cal cu lated for suc ces sively accu mu lated treat ment years (that is, patients with 6 to 11 months of treat ment, patients with 6 to 20 years of treat ment, patients with 6 to 35 years of treat ment, and so on);
3. the "year-by-year approach," in which SMR is cal cu lated for all patients in the first year of treat ment and then cal cu lated for all patients in the sec ond year of treat ment, leav ing out the data of the patients with fewer than 2 years of treat ment, and so on.
Using the cumu la tive approach, one has to make the unproven assump tion that mor tal ity remains sta ble through out any treatment period. How ever, clin i cal expe ri ence indi cates that the pro phy lac tic effect of lith ium is not fully devel oped until after at least 6 months of treat ment; that is, the effect's onset is grad ual, and it seems pos si ble that any mor tal ity-lowering effect of lith ium is also time-dependent.
Unfor tu nately, the cumu la tive approach blurs pos si ble effects of treat ment dura tion on mor tal ity.
Step 2 of Wolf and oth ers' anal y sis reveals that the cumu la tive year-by-year-approach involves a remark able dis tor tion orig i nat ing from the data accu mu la tion pro cess: the num ber of deaths observed in the first year is counted again for the fol low ing year, and so on, arti fi cially increas ing the num ber (41). This effect was not statis ti cally sig nif i cant in the enlarged IGSLI sam ple, because of the large num ber of cases and the long obser va tion peri ods. How ever, if the IGSLI sam ple had acci den tally con sisted of patients with fewer than 19 years of treat ment, this math e mat ical pro ce dure would have shown no reduc tion in mor tal ity dur ing pro phy lac tic treat ment. Thus, the cumu la tive approach can lead to disas trous mis in ter pre ta tion of the data. Another prob lem with the cumu la tive strat egy is its neglect of a basic rule of prob a bil ity the ory: only prob a bil i ties of inde pend ent events may be added up. Being alive in later years of treat ment is depend ent on being alive in ear lier years of treat ment. In the Norton and Whalley (34) and Vestergaard and Aagaard (35) sam ples, the obser va tion peri ods were too small to neu tral ize the dis tort ing effect of the applied cumu la tive approach. There fore, the year-by-year approach is obvi ously the sci entif i cally sounder method of cal cu la tion, dem on strat ing clearly the nor mal ized mor tal ity of lith ium-treated patients dur ing prac ti cally all treat ment peri ods.
Sur vival anal y sis would be a rea son able and prob a bly more appro pri ate method. How ever, this approach is hardly fea sible because eth i cal con sid er ations exclude recruit ing an untreated con trol group of patients with a clear indi ca tion for lith ium pro phy laxis. For this rea son, some uncer tain ties about stud ies on the mor tal ity of patients with manic depres sion cannot be over come.
Antisuicidal Effects of Agents Other Than Lith ium?
Although it has been claimed that the reduced sui cide rates recently observed in var i ous Euro pean coun tries may be attrib ut able to the increased use of mod ern anti de pres sive agents (42, 43) , evi dence does not exist that long-term antidepres sant treat ment in affec tive dis or ders low ers the life time sui cide risk (44) . A pre lim i nary report by Angst and oth ers pointed to a poten tial mor tal ity-reducing effect of antidepres sant treat ment; how ever, many ques tions regard ing details of treat ment con di tions remain unan swered in this paper (19) .
A post hoc anal y sis from a con trolled study com par ing lith ium and carbamazepine in BD and schizoaffective dis or der over 2.5 years pro vides strong evi dence for the antisuicidal effect of lith ium, con trasted with carbamazepine: in the carbamazepine group, 4 com pleted sui cides and 5 sui cidal acts occurred. Con versely, no sui cidal act was observed in the lith ium group (45) (46) (47) . No com pa ra ble data exist for other anticonvulsants used as mood sta bi liz ers or for atyp i cal neuroleptics. The only excep tion is clozapine, which has shown con vinc ing evi dence of an antisuicidal effect in schizophre nia patients (48) .
Although Baldessarini and oth ers pos tu lated that the reduction of the sui cide risk by lith ium pro phy laxis is pri mar ily caused by its depres sion-preventing effect (49) , other authors point to the sero to nin-agonistic and antiaggressive effects of lithium. For exam ple, Ahrens and Müller-Oerlinghausen recently reanalyzed data from the IGSLI study and sug gested that lith ium's antisuicidal prop erty may be rather spe cific; that is, it is not shared by other mood sta bi liz ers and does not depend fully on the pre ven tion of depres sive epi sodes (50) .
The intrigu ing issue of a poten tial spec i fic ity of the lith ium effect will be clar i fied in an ongo ing dou ble-blind, pla cebo-controlled 
How Many Sui cides in the Pop u la tion Can Be Pre vented by Lith ium Pro phy laxis?
Based on data col lected within the Epi de mi o log i cal Catchment Area Study (ECA; 51) and the epi de mi o log i cal data of Weeke (41), as well as on the assump tion that approx i mately 60% of all sui cides in the pop u la tion are com mit ted by patients with affec tive dis or ders, Ahrens and Müller-Oerlinghausen con structed a model for cal cu lat ing deaths and sui cides to be expected in the gen eral pop u la tion and in patients with affec tive dis or ders (50) . Table 4 shows that, for a sam ple of 827 sub jects in the gen eral pop u la tion (matched with patients from the IGSLI sam ple) 1.34 sui cides should be expected; in a cor re spond ing sam ple of patients with affec tive dis or ders, 31 to 37 (aver age, 34) sui cides were pre dicted. In the lith ium-treated IGSLI sam ple, 7 sui cides were observed. In other words, 27 pre dicted sui cides did not occur. Based on this model, we can con clude that 5 sui cides yearly per 1000 treated patients can be pre vented. This would result in approx i mately 250 sui cides pre vented yearly in Germany. The IGSLI data also show that the aver age age of patients who com mit ted sui cide was 44 years. Thus, with out these sui cides, gross national pro duc tiv ity in Ger many would gain 3060 work ing years before age 65 years.
This pos i tive effect adds to the net gain of about 110 mil lion EURO yearly in Ger many result ing from lith ium pro phy laxis within the National Health Scheme, although, as out lined above, the num ber of lith ium-treated patients in this coun try appears to be very low (52) .
Inte grating Mor tal ity Find ings Into Operationalized Treat ment Deci sions
In the treat ment of affec tive dis or ders, the dev as tat ing course of ill ness and the high mor tal ity demand an effec tive, safe, and evi dence-based strat egy. In this con text, psy chi a trists may listen to a com ment on exist ing mor tal ity stud ies made by Mogens Schou in 1998:
Owing to the spe cial prob lems of mor tal ity research this obser va tion can not prove def i nitely that lith ium treat ment has a mor tal ity-lowering, antisuicidal effect. But they are com pati ble with such an assump tion. As sci en tists we con cede that such an action of lith ium remains a pos si bil ity. As cli ni cians we can not afford to dis re gard that pos si bil ity. It must be the duty of psy chi a trists to keep this in mind when they choose pro phy lac tic treat ment for patients with severe depres sions or sui cidal thoughts or sui cide attempts in the past (37).
Con se quently, our research group has devel oped suit able and ratio nal algo rithms for select ing an appro pri ate pro phy lac tic strat egy to treat either uni po lar dis or der or BD (53) . Fig ure 1 offers an exam ple.
Résumé : L'effet antisuicidaire et réducteur de la mortalité du traitement au lith ium : conséquences pour les lignes directrices de la psychiatrie clinique La mortalité liée au sui cide chez les pa tients souffrant de trou bles affectifs est en vi ron 30 fois plus élevée, et la mortalité générale de 2 à 3 fois plus élevée que la mortalité liée au sui cide de la pop u lation générale. Le lith ium a démontré des effets antisuicidaires possiblement spécifiques, en plus de son efficacité prophylactique : il réduit significativement la mortalité excessivement élevée des patients souffrant de trou bles affectifs. À ce jour, les effets de prévention du sui cide n'ont pas été démontrés pour les traitements aux antidépresseurs ou aux anticonvulsivants. La clozapine sem ble réduire le taux de sui cide chez les pa tients schizophrènes. Dans ce contexte, les lignes directrices et les algorithmes pour le choix d'une stratégie prophylactique appropriée dans les trou bles affectifs devraient tenir compte de la présence de la suicidabilité dans les antécédents des pa tients. Le traitement approprié au lith ium prévient quelque 250 sui cides par année en Allemagne, bien que les sels de lith ium ne soient pas souvent prescrits dans le tab leau de la santé nationale (précisément, à 0,06 % de la pop u la tion). Les stratégies rationnelles de traitement réclameraient probablement des taux 10 fois plus élevés.
